Mirum Pharmaceuticals, Inc. (MIRM) Key Metrics
MIRM valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $5.20B
- Enterprise value
- $6.13B
- P/E (TTM)
- —
- Forward P/E
- 166.7
- PEG ratio
- —
- Price / sales
- 8.4 10-yr median 8.1
- Price / book
- 26.6 10-yr median 4.7
- EV / EBITDA
- 341.2
- Dividend yield
- —
- Beta
- 0.61
MIRM key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMIRM valuation Price multiples at each fiscal year-end price.
MIRM returns How much profit the business earns on the capital it uses.
MIRM per-share figures Results divided by the shares outstanding at year-end.
MIRM financial health Debt, liquidity and how easily interest is covered.
MIRM efficiency & capital use Working capital cycle and where the cash goes.
MIRM valuation history
MIRM returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MIRM debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MIRM cash returned to shareholders
MIRM price vs earnings per share
MIRM key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $3.97B | $1.97B | $1.21B | $662.7M | $483.6M | $440.9M | $563.7M | — |
| Enterprise value | $3.90B | $2.00B | $1.23B | $513.1M | $329.7M | $212.3M | $450.7M | — |
| Price / sales | 7.6 | 5.8 | 6.5 | 8.6 | 25.3 | 40.1 | — | — |
| Price / book | 12.6 | 8.7 | 4.9 | 4.7 | 4.0 | 2.6 | 4.3 | — |
| Price / free cash flow | 72.3 | 210.6 | — | — | — | — | — | — |
| Price / operating cash flow | 71.0 | 190.3 | — | — | — | — | — | — |
| EV / sales | 7.5 | 5.9 | 6.6 | 6.7 | 17.2 | 19.3 | — | — |
| EV / EBITDA | 226.7 | — | — | — | — | — | — | — |
| EV / free cash flow | 71.1 | 214.6 | — | — | — | — | — | — |
| Earnings yield | −0.6% | −4.5% | −13.5% | −20.5% | −17.4% | −23.4% | −9.3% | — |
| Free cash flow yield | 1.4% | 0.5% | −7.5% | −18.2% | −31.4% | −20.3% | −7.0% | — |
| Dividend yield | — | — | — | 0.8% | 0.0% | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.8% | 0.0% | 0.0% | 0.0% | — |
| Share price at fiscal year-end | $78.99 | $41.35 | $29.52 | $19.50 | $15.95 | $17.46 | $24.52 | — |
| Per share | ||||||||
| Revenue per share | $10.39 | $7.09 | $4.56 | $2.27 | $0.63 | $0.44 | $0.00 | $0.00 |
| Earnings per share | −$0.47 | −$1.85 | −$4.00 | −$3.99 | −$2.77 | −$4.09 | −$2.29 | −$0.75 |
| Operating cash flow per share | $1.11 | $0.22 | −$1.74 | −$3.54 | −$4.38 | −$3.53 | −$1.71 | −$0.02 |
| Free cash flow per share | $1.09 | $0.20 | −$2.23 | −$3.54 | −$5.01 | −$3.54 | −$1.72 | −$0.34 |
| Cash per share | $7.64 | $5.90 | $7.00 | $4.46 | $5.16 | $9.18 | $5.07 | $2.26 |
| Book value per share | $6.27 | $4.75 | $6.08 | $4.18 | $3.96 | $6.82 | $5.67 | −$0.45 |
| Tangible book value per share | $1.07 | −$0.51 | −$0.10 | $2.44 | $3.35 | $6.82 | $5.67 | −$0.45 |
| Dividends per share | — | — | — | $0.16 | $0.00 | — | — | $0.00 |
| Capex per share | $0.02 | $0.02 | $0.49 | $0.01 | $0.63 | $0.01 | $0.01 | $0.33 |
| Debt per share | $6.36 | $6.69 | $7.54 | $0.06 | $0.09 | $0.13 | $0.16 | $0.00 |
| Shares outstanding | 50.2M | 47.5M | 40.9M | 34.0M | 30.3M | 25.3M | 23.0M | 23.0M |
| Change in shares outstanding | +5.6% | +16.2% | +20.3% | +12.1% | +20.1% | +9.8% | 0.0% | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −8.6% | −37.1% | −83.7% | −103.5% | −57.5% | −68.3% | −87.6% | — |
| Return on invested capital (ROIC) | −6.8% | −25.9% | −65.6% | — | — | — | — | — |
| Return on assets (ROA) | −3.1% | −13.4% | −32.7% | −41.9% | −31.4% | −53.3% | −52.9% | −33.4% |
| Return on tangible assets | −4.0% | −20.9% | −41.5% | −46.2% | −30.4% | −42.9% | −35.8% | −33.4% |
| Free cash flow margin | 10.5% | 2.8% | −48.9% | −156.3% | −793.1% | −811.8% | — | — |
| Financial health | ||||||||
| Total debt | $319.5M | $317.8M | $308.1M | $2.2M | $2.6M | $3.3M | $3.6M | $0 |
| Cash & short-term investments | $383.3M | $280.3M | $286.3M | $151.7M | $156.5M | $231.8M | $116.7M | $52.0M |
| Net debt | −$63.9M | $37.4M | $21.8M | −$149.5M | −$153.9M | −$228.6M | −$113.0M | −$52.0M |
| Debt / equity | 1.02 | 1.41 | 1.24 | 0.02 | 0.02 | 0.02 | 0.03 | — |
| Debt / assets | 0.38 | 0.47 | 0.48 | 0.01 | 0.01 | 0.01 | 0.02 | 0.00 |
| Net debt / EBITDA | −3.71 | — | — | — | — | — | — | — |
| Current ratio | 2.67 | 3.10 | 4.45 | 2.94 | 3.91 | 12.80 | 9.13 | 21.22 |
| Quick ratio | 2.55 | 2.93 | 4.19 | 2.85 | 3.88 | 12.80 | 9.13 | 21.22 |
| Interest coverage | -1.5 | -6.1 | -7.2 | -8.2 | -9.9 | -311.3 | -21.6 | — |
| Working capital | $343.9M | $266.2M | $300.5M | $125.5M | $124.0M | $217.9M | $106.3M | $49.5M |
| Invested capital | $250.8M | $263.1M | $270.5M | −$7.5M | −$33.7M | −$56.5M | $17.3M | −$62.3M |
| Tangible asset value | $53.8M | −$24.2M | −$4.3M | $83.1M | $101.5M | $172.1M | $130.3M | −$10.3M |
| Net current asset value | $21.6M | −$52.3M | −$10.4M | −$20.6M | −$7.8M | $167.6M | $103.0M | −$10.3M |
| Graham net-net per share | −$0.79 | −$2.00 | −$1.21 | −$1.13 | −$0.46 | $6.46 | $4.36 | −$0.45 |
| Capital allocation | ||||||||
| Dividends paid | — | — | — | $5.6M | $0 | — | — | $0 |
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | $0 | $0 |
| Capex / revenue | 0.2% | 0.3% | 10.8% | 0.4% | 99.4% | 2.0% | — | — |
| Capex / operating cash flow | 1.7% | 9.6% | — | — | — | — | — | — |
| Capex / depreciation | 0.04 | 0.04 | 1.86 | 0.09 | 19.51 | 0.36 | 0.87 | 1.71 |
| Stock-based compensation / revenue | 13.7% | 14.4% | 18.8% | 35.0% | 120.6% | 114.1% | — | — |
| R&D / revenue | 35.7% | 41.7% | 55.1% | 138.6% | 686.7% | 741.9% | — | — |
| SG&A / revenue | 49.3% | 60.0% | 78.3% | 115.6% | 309.4% | 206.3% | — | — |
| Efficiency | ||||||||
| Days sales outstanding | 70.6 | 79.2 | 90.1 | 67.2 | 41.6 | 0.0 | — | — |
| Days of inventory on hand | 85.8 | 100.0 | 108.2 | 104.4 | 145.1 | — | — | — |
| Days payables outstanding | 44.0 | 49.3 | 62.5 | 263.4 | 1,181.2 | 1,904.7 | 2,039.0 | — |
| Cash conversion cycle (days) | 112.4 | 129.9 | 135.7 | -91.8 | -994.5 | -1,904.7 | — | — |
| Receivables turnover | 5.17 | 4.61 | 4.05 | 5.43 | 8.76 | — | — | — |
| Payables turnover | 8.30 | 7.41 | 5.84 | 1.39 | 0.31 | 0.19 | 0.18 | 0.00 |
| Inventory turnover | 4.25 | 3.65 | 3.37 | 3.50 | 2.52 | — | — | — |
| Asset turnover | 0.69 | 0.51 | 0.37 | 0.24 | 0.07 | 0.06 | 0.00 | 0.00 |
| Average receivables | $100.8M | $73.1M | $46.0M | $14.2M | $2.2M | $0 | — | — |
| Average payables | $12.1M | $11.0M | $8.1M | $8.9M | $6.2M | $3.3M | $1.8M | $269,000 |
| Average inventory | $23.6M | $22.4M | $13.9M | $3.5M | $756,500 | $0 | — | $0 |
| Intangibles / total assets | 31.0% | 37.2% | 39.1% | 16.7% | 6.4% | 0.0% | 0.0% | 0.0% |
Computed from MIRM's annual financial statements (latest annual report filed February 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MIRM valuation and financial ratios
Mirum Pharmaceuticals earned a return on equity of −8.6% and a return on invested capital of −6.8% in fiscal 2025. It ended the year with $319.5 million of debt and $383.3 million in cash and short-term investments, a net cash position of $63.9 million. The share count rose 118.3% from 23.0M to 50.2M over 7 years.
See the MIRM income statement, the MIRM chart for price history, or the MIRM stock overview for the latest quote and news.
MIRM key metrics FAQ
What is Mirum Pharmaceuticals's EV/EBITDA?
Mirum Pharmaceuticals's enterprise value was 226.7 times EBITDA at the end of fiscal 2025 (enterprise value $3.9 billion, EBITDA $17.2 million); the current EV/EBITDA is 341.2.
What is Mirum Pharmaceuticals's return on equity?
Mirum Pharmaceuticals's return on equity (ROE) was −8.6% in fiscal 2025: net income of -$23.4 million on average shareholders' equity of $270.2 million.
What is Mirum Pharmaceuticals's ROIC?
Mirum Pharmaceuticals's return on invested capital was −6.8% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Mirum Pharmaceuticals have?
Mirum Pharmaceuticals had total debt of $319.5 million at the end of fiscal 2025, a debt-to-equity ratio of 1.02 and more cash than debt.
What is Mirum Pharmaceuticals's free cash flow yield?
Mirum Pharmaceuticals generated $54.9 million of free cash flow in fiscal 2025, a free cash flow yield of 1.4% on its market value at year-end ($4.0 billion).
What is Mirum Pharmaceuticals's current ratio?
Mirum Pharmaceuticals's current ratio was 2.67 at the end of fiscal 2025: current assets were 2.67 times current liabilities.